Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
Public ClinicalTrials.gov record NCT01243177. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Study identification
- NCT ID
- NCT01243177
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Enrollment
- 888 participants
Conditions and interventions
Conditions
Interventions
- Carbamazepine-Controlled Release Drug
- Lacosamide Drug
Drug
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2011
- Primary completion
- Jun 30, 2015
- Completion
- Jul 31, 2015
- Last update posted
- Feb 1, 2021
2011 – 2015
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 786 | Alabaster | Alabama | — | — |
| 799 | Huntsville | Alabama | — | — |
| 780 | Phoenix | Arizona | — | — |
| 777 | Little Rock | Arkansas | — | — |
| 795 | Ocala | Florida | — | — |
| 789 | Panama City | Florida | — | — |
| 776 | Port Charlotte | Florida | — | — |
| 779 | Manhattan | Kansas | — | — |
| 874 | Charlotte | North Carolina | — | — |
| 876 | Hickory | North Carolina | — | — |
| 873 | Raleigh | North Carolina | — | — |
| 794 | Oklahoma City | Oklahoma | — | — |
| 881 | Mansfield | Texas | — | — |
| 790 | Madison | Wisconsin | — | — |
| 798 | Casper | Wyoming | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 169 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01243177, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 1, 2021 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01243177 live on ClinicalTrials.gov.